Wall Street’s top pot analyst loves Cronos deal for Altria: ‘Unique entry into cannabis’

12/10/18–Wall Street’s top marijuana analyst, Vivien Azer, likes Marlboro maker Altria’s $1.8 billion investment in Canadian pot company Cronos Group, telling clients the move represents a “unique entry into cannabis.” According Azer, Cronos’ emphasis on rare cannabinoids will likely prove valuable for Altria as it looks to diversify from tobacco and into up-and-coming markets like e-cigarettes and marijuana. Read